Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bolt Biotherapeutics, Inc.

0.3700
+0.01203.35%
Volume:51.75K
Turnover:19.13K
Market Cap:14.19M
PE:-0.22
High:0.3800
Open:0.3709
Low:0.3521
Close:0.3580
Loading ...
Nov 19, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Nov 19, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 19, 2021

Statement Of Changes In Beneficial Ownership

3 - Initial statement of beneficial ownership of securities
Nov 19, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 09, 2021

Major Issues Report

8-K - Current report
Aug 13, 2021

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Aug 12, 2021

Major Issues Report

8-K - Current report
Aug 12, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 02, 2021

Major Issues Report

8-K - Current report
May 13, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2021

Major Issues Report

8-K - Current report
Apr 07, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Mar 31, 2021

Major Issues Report

8-K - Current report
Mar 31, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 19, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 18, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 17, 2021

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Feb 16, 2021

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Feb 11, 2021

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Feb 09, 2021

Major Issues Report

8-K - Current report